<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04982614</url>
  </required_header>
  <id_info>
    <org_study_id>AAAT6912</org_study_id>
    <secondary_id>7200AA19CA 00003</secondary_id>
    <nct_id>NCT04982614</nct_id>
  </id_info>
  <brief_title>HPV Vaccination in HIV Infected and HIV Uninfected Adolescents in Eswatini</brief_title>
  <official_title>A Multi-site, Open-label Non-inferiority Trial to Assess Immunogenicity of Two Doses of the Nonavalent Human Papillomavirus (HPV) Vaccine Among Children, Adolescents and Young Adults (9-26 Years) Living With HIV vs Three Doses of Nonavalent HPV Vaccine Among HIV Uninfected Young Women (15-26 Years) in Eswatini</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Columbia University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Columbia University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multi-site, open-label non-inferiority study of the 9vHPV vaccine among a&#xD;
      population of children, adolescents and young women living with HIV in Eswatini. This&#xD;
      protocol seeks to assess immunogenicity of a two-dose 9vHPV vaccine regimen among girls and&#xD;
      boys (9-14 years) and young women (15-26 years) living with HIV on antiretroviral therapy&#xD;
      versus a three-dose 9vHPV vaccine regimen among HIV uninfected young women (15-26 years) in&#xD;
      Eswatini. The secondary objectives include examining the safety profiles of the two-dose&#xD;
      9vHPV regimen in those living with HIV and the three-dose 9vHPV regimen in HIV-uninfected&#xD;
      young women, as well as measuring the completion of the vaccination series among those living&#xD;
      with HIV and those who are not infected with HIV.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Cervical cancer remains a significant threat to public health worldwide and remains the&#xD;
      leading cause of cancer-associated mortality in women in Sub Saharan Africa. Cervical&#xD;
      cancer-associated morbidity and mortality is preventable through HPV vaccination, and&#xD;
      screening and treatment of pre-cancerous lesions. To date, there is no nationwide HPV&#xD;
      vaccination program in Eswatini and the country is not eligible for Global Alliance for&#xD;
      Vaccines and Immunization (GAVI) procurement of HPV vaccines, and yet the triad of HIV,&#xD;
      sexually transmitted infections (STI) and cervical cancer generates a severe disease burden&#xD;
      warranting immediate introduction of this intervention. Given the global limitations in&#xD;
      vaccine supply and the high cost for procurement, country programs, including in Eswatini,&#xD;
      must optimize vaccine resources in order to maximize HPV vaccine coverage.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 2022</start_date>
  <completion_date type="Anticipated">May 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">May 31, 2023</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Anti-HPV geometric mean antibody titers</measure>
    <time_frame>Month 7 (4 weeks post Month 6 vaccine dose)</time_frame>
    <description>Serum antibodies against HPV antigens (IgG, IFNg, TNF, IL2, CXCL10, granzyme, perforin, PTX3). Geometric mean titers will be summarized by treatment group, and the ratios of mean GMTs between treatment and control and their 95% confidence intervals calculated around point estimates.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of seroconversions</measure>
    <time_frame>Month 7 (4 weeks post Month 6 vaccine dose)</time_frame>
    <description>Number of participants who seroconvert, defined as having no HPV antibodies pre-vaccination, but detectable HPV antibodies at 4 weeks post month 6 vaccine dose</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of participants with serious adverse events (SAE)</measure>
    <time_frame>Up to 6 months</time_frame>
    <description>Number of participants who reported experiences of SAE. SAE is defined as those that experienced death, life-threatening conditions or hospitalizations.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants completing vaccination series</measure>
    <time_frame>Up to 6 months</time_frame>
    <description>Number of eligible participants completing the 2-dose or 3-dose regimens will be tallied.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">1400</enrollment>
  <condition>HPV Infection</condition>
  <condition>Hiv</condition>
  <condition>HPV Vaccine</condition>
  <arm_group>
    <arm_group_label>2-dose regimen group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Boys and girls (aged 9-14 years) and young women (aged 15-26 years) living with HIV will receive a two-dose regimen of the HPV vaccine at baseline (Month 0) and Month 6.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3-dose regimen group (SOC)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>HIV-uninfected young women (aged 15-26 years) will receive the standard of care three-dose regimen of the HPV vaccine at baseline (Month 0), Month 2 and Month 6.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Gardasil Â® 9</intervention_name>
    <description>GARDASIL 9 is a vaccine indicated in girls and women 9 through 45 years of age for the prevention of the following diseases: Cervical, vulvar, vaginal, and anal cancer, and Genital warts (condyloma acuminata) caused by Human Papillomavirus (HPV).&#xD;
0.5-mL suspension for intramuscular injection as a single-dose vial and prefilled syringe at the following regimen/schedule: 9 through 14 years - 2-dose at 0, 6 to 12 months OR 3-dose at 0, 2, 6 months 15 through 45 years - 3-dose at 0, 2, 6 months</description>
    <arm_group_label>2-dose regimen group</arm_group_label>
    <arm_group_label>3-dose regimen group (SOC)</arm_group_label>
    <other_name>Human Papillomavirus 9-valent Vaccine, Recombinant</other_name>
    <other_name>9vHPV vaccine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        For people living with HIV receiving two-dose regimen:&#xD;
&#xD;
          -  Females 9-26 years and males 9-14 years,&#xD;
&#xD;
          -  Documented HIV infection,&#xD;
&#xD;
          -  Aware of HIV+ status,&#xD;
&#xD;
          -  Currently receiving antiretroviral treatment (ART) for HIV infection for at least six&#xD;
             months,&#xD;
&#xD;
          -  Living in Eswatini,&#xD;
&#xD;
          -  For individuals 18+ years: able to provide informed consent,&#xD;
&#xD;
          -  For individuals 15-17 years: able to provide informed assent,&#xD;
&#xD;
          -  For individuals 9-14 years of age: able to provide informed assent AND accompanied by&#xD;
             an adult caregiver who is able to give informed consent,&#xD;
&#xD;
          -  Intending to remain in the vicinity of the study sites for the study period&#xD;
&#xD;
        For reference group of HIV-uninfected women receiving three-dose regimen:&#xD;
&#xD;
          -  Females 15-26 years,&#xD;
&#xD;
          -  Documented negative HIV test at baseline&#xD;
&#xD;
          -  Living in Eswatini,&#xD;
&#xD;
          -  Able to provide informed assent (15-17 years) or informed consent (18-26 years)&#xD;
&#xD;
          -  Intending to remain in the vicinity of the study sites for the study period&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        For all participants:&#xD;
&#xD;
          -  Diagnosis of other immunosuppressive diseases or receipt of immunosuppressive&#xD;
             medications,&#xD;
&#xD;
          -  Diagnosis of other acute or chronic illness,&#xD;
&#xD;
          -  Receipt of other vaccinations within 2-3 weeks before or after study vaccination,&#xD;
&#xD;
          -  Receipt of blood-derived products within 6 months before or during the study,&#xD;
&#xD;
          -  Previous receipt of an HPV vaccine,&#xD;
&#xD;
          -  Currently pregnant,&#xD;
&#xD;
          -  Known allergies to a vaccine component&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>9 Years</minimum_age>
    <maximum_age>26 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Elaine Abrams, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Columbia University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Xolisile Dlamini</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ministry of Health, Eswatini</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Harriet Nuwagaba-Biribonwoha, MD, PhD</last_name>
    <phone>+268 24045797</phone>
    <email>hn2158@cumc.columbia.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Bhekumusa Lukhele, PhD</last_name>
    <phone>+268 24096000</phone>
    <email>blukhele@baylorswaziland.org.sz</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Bulembu Clinic</name>
      <address>
        <city>Bulembu</city>
        <country>Swaziland</country>
      </address>
    </facility>
    <contact>
      <last_name>Harriet Nuwagaba-Biribonwoha, MD, PhD</last_name>
      <phone>+268 24045797</phone>
      <email>hn2158@cumc.columbia.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hlathikhulu Government Hospital</name>
      <address>
        <city>Hlatikulu</city>
        <country>Swaziland</country>
      </address>
    </facility>
    <contact>
      <last_name>Harriet Nuwagaba-Biribonwoha, MD, PhD</last_name>
      <phone>+268 24045797</phone>
      <email>hn2158@cumc.columbia.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>AHF Lamvelase</name>
      <address>
        <city>Manzini</city>
        <country>Swaziland</country>
      </address>
    </facility>
    <contact>
      <last_name>Harriet Nuwagaba-Biribonwoha, MD, PhD</last_name>
      <phone>+268 24045797</phone>
      <email>hn2158@cumc.columbia.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Raleigh Fitkin Memorial Hospital</name>
      <address>
        <city>Manzini</city>
        <country>Swaziland</country>
      </address>
    </facility>
    <contact>
      <last_name>Harriet Nuwagaba-Biribonwoha, MD, PhD</last_name>
      <phone>+268 24045797</phone>
      <email>hn2518@cumc.columbia.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Baylor College of Medicine - Bristol Myers-Squibb Children's Clinical Centre of Excellence</name>
      <address>
        <city>Mbabane</city>
        <country>Swaziland</country>
      </address>
    </facility>
    <contact>
      <last_name>Harriet Nuwagaba-Biribonwoha, MD, PhD</last_name>
      <phone>+268 24045797</phone>
      <email>hn2158@cumc.columbia.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Good Shephard Hospital</name>
      <address>
        <city>Siteki</city>
        <country>Swaziland</country>
      </address>
    </facility>
    <contact>
      <last_name>Harriet Nuwagaba-Biribonwoha, MD, PhD</last_name>
      <phone>+268 24045797</phone>
      <email>hn2158@cumc.columbia.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>Swaziland</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>July 20, 2021</study_first_submitted>
  <study_first_submitted_qc>July 20, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 29, 2021</study_first_posted>
  <last_update_submitted>October 5, 2021</last_update_submitted>
  <last_update_submitted_qc>October 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Columbia University</investigator_affiliation>
    <investigator_full_name>Elaine J. Abrams, MD</investigator_full_name>
    <investigator_title>Professor of Pediatrics and Epidemiology</investigator_title>
  </responsible_party>
  <keyword>HPV</keyword>
  <keyword>Adolescents living with HIV</keyword>
  <keyword>HPV immunogenicity</keyword>
  <keyword>Vaccine adherence</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Papillomavirus Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Data sharing plan is still under development. The plan will follow all in-country requirements for research conducted in Eswatini.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

